Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203

J Clin Oncol. 2025 Sep;43(25):2840. doi: 10.1200/JCO-25-01680. Epub 2025 Jul 24.
No abstract available

Publication types

  • Published Erratum